search
Back to results

99mTc Labeled Anti-PD-L1 sdAb SPECT/CT in Assessment of PD-L1 Expression in NSCLC

Primary Purpose

Non-Small Cell Lung Cancer

Status
Completed
Phase
Early Phase 1
Locations
China
Study Type
Interventional
Intervention
Injection of 99m-Tc-NM-01
Sponsored by
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Non-Small Cell Lung Cancer

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Participant is willing and able to give informed consent for the participation in the study before any protocol-specific screening procedures are performed
  • Male or female, aged 18-75 years old
  • Previous diagnosis of non-small cell carcinoma, confirmed with pathology tests
  • AST, ALT, BUN, Cr not more than double the normal values
  • Patients with no current history of hepatitis A, hepatitis B, AIDS, tuberculosis and other infectious diseases

Exclusion Criteria:

  • Severe infection
  • Unable to provide biopsy sample for testing PD-L1 expression level
  • Patients with pacemakers
  • Pregnant and lactating women
  • Investigators professional decision that the subject should not participate in this clinical study

Sites / Locations

  • Shanghai General Hospital

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Injection of 99m-Tc-NM-01

Arm Description

All patients with NSCLC who have undergone biopsy of primary tumour lesion will be administered 3-12 MBq/kg of 99m-Tc-NM-01 in a single injection.

Outcomes

Primary Outcome Measures

Visual Assessment of PD-L1 expression in NSCLC using 99m-Tc-NM-01 SPECT/CT Scan
Visual analysis will be carried out by 4 experienced nuclear medicine physicians to observe the uptake of 99m-Tc-NM-01 in lung lesions.A 4 point system will be used to interpret the scans for abnormalities. It is categorised as such: score 0, no abnormal increased uptake; score 1, low increased uptake; score 2, moderate increased uptake; score 3, high increased uptake. The lesion will be considered positive for malignancy if the score is 2 or higher.
Semiquantitative Assessment of Lung Lesions in 99m-Tc-NM-01 SPECT/CT Scan
Each patient will be administered 3-12 MBq/kg of 99m-Tc-NM-01 and the semiquantitative analysis of the region of interest (ROI) will be performed in lung lesions. Higher level of PD-L1 expression (Tumor proportion score, TPS), higher ROI in tumor. No expression TPS < 1%; Low expression TPS 1 - 49%; High expression TPS ≥ 50%.

Secondary Outcome Measures

PD-L1 expression levels
Patients biopsy sample will be tested to confirm the levels of PD-L1 expression using Human PD-L1 ELISA Kit.
Adverse Drug Reaction Report
Monitor adverse events within 7 days after the injection and scanning to establish the safety of 99m-Tc-NM-01 in patients.
New tumor lesion detection
SPECT/CT scans using 99m-Tc-NM-01 may detect new tumor areas, which can be further proven by biopsy method in order to rule out any false positive results.

Full Information

First Posted
November 22, 2016
Last Updated
April 13, 2023
Sponsor
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Collaborators
NanoMab Technology (UK) Limited
search

1. Study Identification

Unique Protocol Identification Number
NCT02978196
Brief Title
99mTc Labeled Anti-PD-L1 sdAb SPECT/CT in Assessment of PD-L1 Expression in NSCLC
Official Title
99mTc Labeled Anti-PD-L1 sdAb in SPECT/CT Assessment of Programmed Death Ligand-1 Expression in Non-small Cell Lung Cancer
Study Type
Interventional

2. Study Status

Record Verification Date
April 2023
Overall Recruitment Status
Completed
Study Start Date
February 15, 2018 (Actual)
Primary Completion Date
December 31, 2022 (Actual)
Study Completion Date
December 31, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Collaborators
NanoMab Technology (UK) Limited

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
To evaluate the safety, dosimetry and efficacy of 99m-Tc labeled anti-PD-L1 single domian antibody (sdAb) (Product Code Name: 99mTc-NM-01)SPECT/CT in the diagnostic imaging PD-L1 expression in Non-Small Cell Lung Cancer (NSCLC) and compare it with the existing gold standard "biopsy PD-L1 detection". It is also to establish a new clinical method of non-invasive PD-L1 expression detection in NSCLC using 99m-Tc labeled anti-PD-L1 sdAb.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Non-Small Cell Lung Cancer

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Early Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
30 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Injection of 99m-Tc-NM-01
Arm Type
Experimental
Arm Description
All patients with NSCLC who have undergone biopsy of primary tumour lesion will be administered 3-12 MBq/kg of 99m-Tc-NM-01 in a single injection.
Intervention Type
Procedure
Intervention Name(s)
Injection of 99m-Tc-NM-01
Intervention Description
Patient is injected with micro-dose of 99m-Tc-NM-01
Primary Outcome Measure Information:
Title
Visual Assessment of PD-L1 expression in NSCLC using 99m-Tc-NM-01 SPECT/CT Scan
Description
Visual analysis will be carried out by 4 experienced nuclear medicine physicians to observe the uptake of 99m-Tc-NM-01 in lung lesions.A 4 point system will be used to interpret the scans for abnormalities. It is categorised as such: score 0, no abnormal increased uptake; score 1, low increased uptake; score 2, moderate increased uptake; score 3, high increased uptake. The lesion will be considered positive for malignancy if the score is 2 or higher.
Time Frame
1 year
Title
Semiquantitative Assessment of Lung Lesions in 99m-Tc-NM-01 SPECT/CT Scan
Description
Each patient will be administered 3-12 MBq/kg of 99m-Tc-NM-01 and the semiquantitative analysis of the region of interest (ROI) will be performed in lung lesions. Higher level of PD-L1 expression (Tumor proportion score, TPS), higher ROI in tumor. No expression TPS < 1%; Low expression TPS 1 - 49%; High expression TPS ≥ 50%.
Time Frame
1 year
Secondary Outcome Measure Information:
Title
PD-L1 expression levels
Description
Patients biopsy sample will be tested to confirm the levels of PD-L1 expression using Human PD-L1 ELISA Kit.
Time Frame
1 year
Title
Adverse Drug Reaction Report
Description
Monitor adverse events within 7 days after the injection and scanning to establish the safety of 99m-Tc-NM-01 in patients.
Time Frame
7 days
Title
New tumor lesion detection
Description
SPECT/CT scans using 99m-Tc-NM-01 may detect new tumor areas, which can be further proven by biopsy method in order to rule out any false positive results.
Time Frame
1 year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Participant is willing and able to give informed consent for the participation in the study before any protocol-specific screening procedures are performed Male or female, aged 18-75 years old Previous diagnosis of non-small cell carcinoma, confirmed with pathology tests AST, ALT, BUN, Cr not more than double the normal values Patients with no current history of hepatitis A, hepatitis B, AIDS, tuberculosis and other infectious diseases Exclusion Criteria: Severe infection Unable to provide biopsy sample for testing PD-L1 expression level Patients with pacemakers Pregnant and lactating women Investigators professional decision that the subject should not participate in this clinical study
Facility Information:
Facility Name
Shanghai General Hospital
City
Shanghai
Country
China

12. IPD Sharing Statement

Citations:
PubMed Identifier
22658127
Citation
Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012 Jun 28;366(26):2443-54. doi: 10.1056/NEJMoa1200690. Epub 2012 Jun 2.
Results Reference
background
PubMed Identifier
20516446
Citation
Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller TL, Gilson MM, Wang C, Selby M, Taube JM, Anders R, Chen L, Korman AJ, Pardoll DM, Lowy I, Topalian SL. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010 Jul 1;28(19):3167-75. doi: 10.1200/JCO.2009.26.7609. Epub 2010 Jun 1.
Results Reference
background
PubMed Identifier
26273411
Citation
Zhang J, Gao J, Li Y, Nie J, Dai L, Hu W, Chen X, Han J, Ma X, Tian G, Wu D, Shen L, Fang J. Circulating PD-L1 in NSCLC patients and the correlation between the level of PD-L1 expression and the clinical characteristics. Thorac Cancer. 2015 Jul;6(4):534-8. doi: 10.1111/1759-7714.12247. Epub 2015 Mar 5.
Results Reference
background
PubMed Identifier
25977331
Citation
Heskamp S, Hobo W, Molkenboer-Kuenen JD, Olive D, Oyen WJ, Dolstra H, Boerman OC. Noninvasive Imaging of Tumor PD-L1 Expression Using Radiolabeled Anti-PD-L1 Antibodies. Cancer Res. 2015 Jul 15;75(14):2928-36. doi: 10.1158/0008-5472.CAN-14-3477. Epub 2015 May 14.
Results Reference
background
PubMed Identifier
26554829
Citation
Josefsson A, Nedrow JR, Park S, Banerjee SR, Rittenbach A, Jammes F, Tsui B, Sgouros G. Imaging, Biodistribution, and Dosimetry of Radionuclide-Labeled PD-L1 Antibody in an Immunocompetent Mouse Model of Breast Cancer. Cancer Res. 2016 Jan 15;76(2):472-9. doi: 10.1158/0008-5472.CAN-15-2141. Epub 2015 Nov 10.
Results Reference
background
PubMed Identifier
33259032
Citation
Hughes DJ, Chand G, Goh V, Cook GJR. Inter- and intraobserver agreement of the quantitative assessment of [99mTc]-labelled anti-programmed death-ligand 1 (PD-L1) SPECT/CT in non-small cell lung cancer. EJNMMI Res. 2020 Dec 1;10(1):145. doi: 10.1186/s13550-020-00734-x.
Results Reference
derived

Learn more about this trial

99mTc Labeled Anti-PD-L1 sdAb SPECT/CT in Assessment of PD-L1 Expression in NSCLC

We'll reach out to this number within 24 hrs